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Mapping and direct valuation: do they give
equivalent EQ-5D-5L index scores?
Nan Luo1, Yin Bun Cheung2,3,4, Raymond Ng5 and Chun Fan Lee2,3*
Abstract
Objective: Utility values of health states defined by health-related quality of life instruments can be derived from
either direct valuation (‘valuation-derived’) or mapping (‘mapping-derived’). This study aimed to compare the utility-
based EQ-5D-5L index scores derived from the two approaches as a means to validating the mapping function
developed by van Hout et al for the EQ-5D-5L instrument.
Methods: This was an observational study of 269 breast cancer patients whose EQ-5D-5L index scores were
derived from both methods. For comparing discriminatory ability and responsiveness to change, multivariable
regression models were used to estimate the effect sizes of various health indicators on the index scores.
Agreement and test-retest reliability were examined using intraclass correlation coefficient (ICC). Whenever
appropriate, the 90 % confidence intervals (90 % CI) were compared to predefined equivalence margins.
Results: The mean difference in and ICC between the valuation- and mapping-derived EQ-5D-5L index scores were
0.015 (90 % CI = 0.006 to 0.024) and 0.915, respectively. Discriminatory ability and responsiveness of the two indices
were equivalent in 13 of 15 regression analyses. However, the mapping-derived index score was lower than the
valuation-derived index score in patients experiencing extreme health problems, and the test-retest reliability of the
former was lower than the latter, for example, their ICCs differed by 0.121 (90 % CI = 0.051 to 0.198) in patients who
reported no change in performance status in the follow-up survey.
Conclusion: This study provided the first evidence supporting the validity of the mapping function for converting
EQ-5D-5L profile data into a utility-based index score.
Introduction
Utility values of health outcomes described by health-
related quality of life (HRQoL) instruments are convenient
quality-of-life weights for calculation of quality-adjusted
life years (QALYs) in cost-utility analysis (CUA) of health
services and technologies [1]. Such values are either dir-
ectly measured using a valuation technique such as time
trade-off or standard gamble (i.e., the valuation approach)
or estimated using a mapping function from known utility
values of health outcomes defined by another HRQoL
instrument (i.e., the mapping approach). For example, the
valuation approach has been taken to determine the utility
values of the health outcomes or states defined by the EQ-
5D-3L questionnaire [2], and the availability of the EQ-
5D-3L utility values in turn has stimulated the application
of the mapping approach to many HRQoL instruments
whose utility values are unknown [3]. Typically, a mapping
function is developed by modeling cross-sectional data
collected using both the source and target instruments
from a group of subjects. The ordinary least-square model
is most frequently used in mapping studies [4].
The EQ-5D-5L is a new HRQoL instrument [5] for
which van Hout et al. [6] have developed a mapping func-
tion based on its relationship with the EQ-5D-3L. Devel-
oped from the EQ-5D-3L, the EQ-5D-5L describes similar
health states as the EQ-5D-3L. Both instruments describe
a respondent's health in terms of mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. While
the EQ-5D-3L describes problems in each dimension into
3 levels (no problems, some/moderate problems, and
unable/extreme problems), the EQ-5D-5L describes into 5
levels (no problems, slight problems, moderate problems,
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severe problems, and unable/extreme problems). There-
fore, the EQ-5D-3L is an ideal source instrument for the
EQ-5D-5L to map into [4]. For estimating the mapping
function, 3691 individuals with conditions of varying
severity recruited from six European countries were sur-
veyed using both the EQ-5D-5L and EQ-5D-3L question-
naires. The mapping function is based on a nonparametric
model for its simplicity and superior fit to the data [6]. For
any respondent of the EQ-5D-5L, this mapping function
gives the corresponding probabilities of the EQ-5D-3L re-
sponse patterns (each pattern corresponds to a health
state). The utility value of the respondent’s health, which is
the corresponding EQ-5D-5L health state, can be calculated
as the sum of the known utility values of the EQ-5D-3L
health states weighted by the corresponding probabilities.
As the EQ-5D-5L utility values determined through the
valuation approach were not available at the time when van
Hout et al. conducted their mapping study, the resultant
mapping function has been recommended as the interim
approach to deriving utility values from EQ-5D-5L data [7].
Mapping is regarded as a ‘second-best’ approach to de-
riving utility values, although it is accepted by NICE as a
legitimate approach to generating utility values for CUA
[8]. Studies found that mapping functions predict values
less extreme than the values which they are used to map
into [9, 10] and when they are validated in external data-
sets [9, 10], suggesting the issue of prediction bias. van
Hout et al’s mapping function may be less susceptible to
this issue because it was not based on a linear regression
model. Fayers and Hays pointed out that any regression
model would predict less extreme values because of the
phenomenon of regression to the mean [11]. Neverthe-
less, the performance of this mapping function has not
been investigated, to the best of our knowledge.
The objective of this study was to validate van Hout
et al’s mapping function for the EQ-5D-5L. The valid-
ation was through comparing the measurement properties
of the utility values generated using van Hout et al’s map-
ping function (hereafter referred to as ‘mapping-derived’
index) and those determined through direct valuation of
the EQ-5D-5L health states using a time trade-off tech-
nique [12] (hereafter referred to as ‘valuation-derived’
index) in patients with breast cancer. We hypothesized
that values derived from the two approaches would have
equivalent measurement properties and result in compar-
able QALYs in CUA and thus van Hout et al’s mapping
function is a valid approach to generating EQ-5D-5L util-
ity values.
Materials and methods
Design and recruitment
This study was approved by the Singapore Health Ser-
vices Institutional Review Board. Patients were recruited
from two sites, namely, the specialist outpatient clinics
of the National Cancer Centre, Singapore, and the on-
cology wards of the Singapore General Hospital. Eligibil-
ity criteria were: histologically confirmed breast cancer;
21 years old or above; ability to understand Chinese or
English or both; no evidence of brain metastasis, psych-
osis or severe depression; and willingness to give in-
formed consent. Patients answered an identical Chinese
or English questionnaire package according to their pref-
erence. Each package included the EQ-5D-5L self-report
questionnaire, the Functional Assessment of Cancer
Therapy - Breast (FACT-B) questionnaire [13, 14], and
questions assessing demographic and performance sta-
tus. Performance status was assessed using a Likert rat-
ing scale ranging from 0 (without symptoms) to 4
(bedridden), excluding the score 5 (death) which is not
applicable in this study [15]. This measure is strongly as-
sociated with cancer patients’ quality of life, and can be
self-administered [16, 17]. The questionnaire package
was self-administered or by a research assistant upon re-
quest. Interviewer administration is often unavoidable in
practice and is allowed by developers of both instru-
ments (http://www.euroqol.org, accessed Jan 19, 2015;
http://www.facit.org, assessed Jan 19, 2015). Patients’
managing oncologists also assessed the patients using
the above-mentioned performance scale. Other clinical
information was retrieved from medical records.
All patients were sent a similar questionnaire package
for completion one to two weeks after the baseline sur-
vey. In addition to the health-status and performance
scales, the follow-up survey package included a question
assessing the change in health status using a 7-point
Likert scale ranging from ‘very much better’ to ‘very
much worse’. Up to two reminders with the question-
naire package were sent to non-respondents.
Instruments
The EQ-5D-5L contains five questions, each assessing one
health dimension including mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression. Each ques-
tion asked respondents to describe their health status on
the day of survey as one of five levels including ‘no prob-
lems’, ‘slight problems’, ‘moderate problems’, ‘severe prob-
lems’, and ‘unable to (do)’ (for mobility, self-care, and
usual activities) or ‘extreme problems’ (for pain/discom-
fort and anxiety/depression) [5]. The questionnaire also
includes a vertical, hash-marked visual analogue scale
(EQ-VAS) anchored by 0 (the worst imaginable health
state) at the bottom and 100 (the best imaginable health
state) on the top for respondents to rate their overall
health. The English and Chinese versions of the EQ-5D-
5L questionnaire for use in Singapore are very similar in
wording to their counterparts in the UK and China, and
exhibited similar measurement properties [18, 19]. The
EQ-5D-5L has been found to have better psychometric
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properties than the EQ-5D-3L in many patient popula-
tions [20–24].
The FACT-B is a breast cancer-specific health-related
quality of life instrument of the Functional Assessment
of Chronic Illness Therapy Measurement System for
chronic diseases. The English and Chinese FACT-B
version 4 consist of 37 items that are divided into five
subscales (physical, social/family, emotional, functional
well-beings, and additional concerns for breast cancer)
[13, 14]. Each item is rated on a 5-point Likert scale.
Negatively worded items were recoded so that a higher
score indicates a better health-related quality of life. The
FACT-B total score is the sum of scores of all five sub-
scales, ranging from 0 to 144, while the FACT-General
(FACT-G) total score is the sum of scores of the phys-
ical, social/family, emotional, functional well-beings sub-
scales, ranging from 0 to 108. Missing values are
imputed by the half-rule [25]. The validity and reliability
of, and the comparability between the English and
Chinese versions of the FACT-B have been previously
demonstrated [19, 26].
Statistical analysis
The valuation-derived EQ-5D-5L index score was calcu-
lated using an algorithm recently developed by Ramos-
Goñi et al. [12]. This algorithm was developed using
utility values of 86 EQ-5D-5L health states directly mea-
sured from a general population sample (N = 1000) in
Spain using both the time trade-off and the discrete
choice experiment methods. The two valuation methods
were described in detail elsewhere [27]. Briefly, in time
trade-off, a series of questions each asking a respondent
to choose between a shorter but healthier life and a lon-
ger life in an impaired health state; in discrete choice ex-
periment, respondents were asked to answer a set of
independent questions each requiring the respondents
to indicate preference between two multi-dimensional
health states whose superiority is not obvious (e.g., one
health state featured by pain and the other featured by
depression). The EQ-5D-5L index scores generated
using this algorithm range from −0.224 to 1, with 0, 1,
and negative values corresponding to death, full health,
and health states worse than death, respectively.
The mapping-derived EQ-5D-5L index score was cal-
culated using van Hout et al’s mapping function [6] and
the Spanish EQ-5D-3L utility values [28]. The EQ-5D-
3L values were determined through the direct valuation
approach from a general population sample (N = 1000)
in Spain using a time trade-off method very similar to
the one used in the abovementioned EQ-5D-5L valu-
ation study. The Spanish EQ-5D-3L values range from
−0.654 to 1, with 0, 1, and negative scores correspond-
ing to death, full health, and health states worse than
death, respectively. An Excel-based calculator developed
by the EuroQol Research Foundation (Bas Janssen,
personal communication) was used to perform the
calculation.
The means scores and their standard deviations of the
two indices were compared for the entire sample and
subgroups of patients with different demographic and
clinical characteristics. The agreement of the two indices
was examined using the intraclass correlation coefficient
(ICC) and Bland-Altman plot, and the equivalence of
the two indices was assessed by comparing the 90 %
confidence interval (CI) of the differences with the pre-
defined equivalence margin of 0.05. The 90 % CI [29]
and the equivalence margin of ±0.05 [30, 31] were
chosen to be consistent with previous studies.
The discriminatory power, responsiveness to change and
test-retest reliability of the two indices were compared. For
discriminatory power, the two EQ-5D-5L indices were sim-
ultaneously regressed on a health indicator in a bivariate
regression model. Health indicators included oncologist-
assessed and self-assessed performance status, FACT-B
and FACT-G total scores, EQ-VAS, current evidence of
disease and chemo- or radiotherapy. The effect size was
quantified by the regression coefficients, βMapping and
βValuation. The estimate of the coefficients together with
the correlation between them were used to construct a
90 % CI for the difference in effect size, βValuation-βMapping.
Similarly, for responsiveness to change, the effect
size was estimated by regressing the change in the EQ-
5D-5L index scores using both value sets from baseline
to follow-up on the change in a health indicator in a
bivariate regression model. The 90 % CI for the differ-
ence in effect size was estimated and compared with
the equivalence margin. Only patients who reported in
the follow-up survey a change in performance or
health status were included in the responsiveness ana-
lysis. To deal with the potential regression-to-the-
mean effect, analyses were adjusted for the baseline
scores. This is a recommended approach for analysis of
change in clinical trials [32]. Moreover, the change in
scores between baseline and follow-up surveys was
compared between the two indices to assess equiva-
lence. As change in utility scores in clinical trials is
used to calculate quality-adjusted life years in cost-
utility analysis, equivalence in changed scores rather
than absolute scores of the two indices in baseline or
follow-up determines whether the two indices would
lead to equivalent results when used in economic
evaluations.
For test-retest reliability, ICC of the two EQ-5D-5L indi-
ces was calculated using patients who returned the follow-
up questionnaire within 30 days after the baseline survey
and reported no change in performance or health status at
follow-up. Since the two indices are highly correlated, a
90 % CI for the difference in ICC was constructed using
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the method proposed by Ramasundarahettige et al. [33].
In the comparison of reliability, we also adopted an
equivalence margin of ±0.05. Bland-Altman plots [34, 35]
were also generated to assess the test-retest reliability of
the two indices.
Results
A total of 280 patients completed the baseline survey.
Two patients with missing values and nine proxy-
administered patients were excluded, leaving 269 pa-
tients. Table 1 summarizes their demographic and
clinical characteristics. The mean (standard deviation)
score of the valuation- and mapping-derived EQ-5D-5L
indices for the sample was 0.811 (0.186) and 0.796
(0.250), respectively, at baseline (Table 2). The difference
of 0.015 (90 % CI = 0.006 to 0.024) was small in magni-
tude and the 90 % CI totally fell within the equivalence
margin of ±0.05, indicating equivalence of the two indi-
ces. Both indices attained the maximum value of 1, while
the lowest score was −0.111 and −0.370 for the valu-
ation- and mapping-derived index, respectively. The ICC
between the two indices was 0.915. Their Bland-Altman
plot shows that, for the 12 patients (4.5 %) with the low-
est health utility value in the sample, the mapping-
derived index score (mean = −0.118, range = −0.370 to
0.118) was apparently smaller than the valuation-derived
index score (mean = 0.261, range = −0.111 to 0.487)
(Fig. 1). All the 12 patients experienced extreme prob-
lems in at least one EQ-5D-5L dimension.
The valuation-derived index score was generally higher
than the mapping-derived index score in patients with
similar characteristics (Table 2). However, the magnitude
of the difference was small and the corresponding 90 %
CI fell within the pre-specified equivalence margin for
most of the patient groups. The only non-equivalence
was observed in patients with a performance status score
of 3 or above (N = 19, difference = 0.207, 90 % CI = 0.128
to 0.285), the majority of whom (N = 14) reported severe
or extreme problems in at least one of the EQ-5D-5L
dimensions.
Table 3 compares the effect size of the two indices for
detecting a difference in the performance status, evi-
dence of disease, treatment status, FACT-B and FACT-G
total score, and EQ-VAS. For the latter three indicators,
the effect size was presented as the change in EQ-5D-5L
utility index per 20-point increment in the indicator
which is sufficiently large to represent a change in health
status. For each indicator, the mapping-derived index
score showed a larger effect size than the valuation-
derived index score. However, those statistically signifi-
cant differences were small. For 5 out of 7 indicators,
the 90 % CI fell within the pre-specified equivalence
margin of ±0.05, thus confirming equivalence.
In the follow-up survey, 263 (93.9 %) patients returned
completed questionnaires. After excluding patients with
missing responses to the EQ-5D-5L questionnaire (N = 1)
or the self-assessed performance status question (N = 13),
Table 1 Patient characteristics at baseline (N = 269)
Characteristics N (%)
Age, mean (standard deviation) 52.1 (9.9)
Language version
English 169 (62.8)
Chinese 100 (37.2)
Race
Chinese 221 (82.2)
Malay 25 (9.3)
Indian 19 (7.1)
Others 4 (1.5)
Marital status
Married 185 (69.3)
Single 54 (20.2)
Divorced/separated 15 (5.6)
Widowed 13 (4.9)
Education level
Primary or below 69 (25.7)
Secondary 120 (44.8)
Postsecondary 79 (29.5)
Oncologist-assessed performance status
0 140 (52.2)
1 93 (34.7)
2 24 (9.0)
3 or above 11 (4.1)
Patients’ self-assessed performance status
0 102 (37.9)
1 128 (47.6)
2 20 (7.4)
3 or above 19 (7.1)
Patient type
Inpatient 89 (33.1)
Outpatient 180 (66.9)
Current evidence of disease (present) 142 (53.2)
Purpose of visit
Treatment - adjuvant/curative/hormone therapy 118 (44.4)
Treatment - palliative 98 (36.8)
Follow up (no treatment) 50 (18.8)
On chemotherapy/radiotherapy (yes) 116 (43.1)
Mode of interview
Self-administration 244 (90.7)
Interview-administration 25 (9.3)
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78 and 129 patients who reported a change in perform-
ance and health status, respectively, were included in the
analysis of responsiveness to change. Among those, 26
and 108 patients reported improved performance and
health status, respectively. The mean changed score for
those with improved performance status was 0.044 and
0.060 for the valuation- and mapping-derived indices, re-
spectively (difference = −0.016, 90 % CI = −0.028 to −0.003);
for those with improved health status, the correspond-
ing mean changed scores were 0.002 and 0.008 (differ-
ence = −0.006, 90 % CI = −0.014 to 0.003). On the other
hand, 52 and 21 patients reported worsened performance
Table 2 Baseline EQ-5D-5L index scores by demographic and clinical characteristics
Characteristic Mean (standard deviation) Difference (90 %
confidence interval)Valuation-derived index score Mapping-derived index score
All patients 0.811 (0.186) 0.796 (0.250) 0.015 (0.006 to 0.024)a
Language version
English 0.815 (0.182) 0.808 (0.226) 0.007 (−0.001 to 0.015)a
Chinese 0.804 (0.192) 0.774 (0.285) 0.029 (0.009 to 0.050)a
Race
Chinese 0.816 (0.189) 0.799 (0.258) 0.017 (0.007 to 0.028)a
Malay/Indian/others 0.788 (0.169) 0.782 (0.206) 0.006 (−0.010 to 0.022)a
Marital status
Married 0.826 (0.174) 0.816 (0.291) 0.010 (0.000 to 0.020)a
Single/divorced/widowed 0.774 (0.207) 0.745 (0.304) 0.028 (0.009 to 0.048)a
Education level
Primary or below 0.793 (0.219) 0.762 (0.304) 0.031 (0.008 to 0.054)
Secondary 0.818 (0.178) 0.799 (0.249) 0.019 (0.004 to 0.033)a
Post-secondary 0.817 (0.168) 0.820 (0.192) −0.003 (−0.011 to 0.005)a
Oncologist-assessed performance status
0 0.889 (0.120) 0.891 (0.140) −0.002 (−0.008 to 0.005)a
1 0.774 (0.160) 0.766 (0.207) 0.008 (−0.005 to 0.022)a
2 0.612 (0.224) 0.514 (0.360) 0.098 (0.038 to 0.158)
3 or above 0.575 (0.349) 0.457 (0.507) 0.118 (0.025 to 0.210)
Patients’ self-assessed performance status
0 0.917 (0.104) 0.917 (0.127) −0.000 (−0.008 to 0.007)a
1 0.796 (0.132) 0.796 (0.160) 0.000 (−0.009 to 0.009)a
2 0.739 (0.159) 0.728 (0.182) 0.011 (−0.008 to 0.030)a
3 or above 0.421 (0.271) 0.214 (0.419) 0.207 (0.128 to 0.285)b
Patient type
Inpatient 0.704 (0.228) 0.650 (0.338) 0.054 (0.029 to 0.078)
Outpatient 0.864 (0.133) 0.868 (0.146) −0.004 (−0.008 to 0.001)a
Current evidence of disease
Absent 0.875 (0.132) 0.878 (0.151) −0.003 (−0.010 to 0.004)a
Present 0.753 (0.208) 0.721 (0.294) 0.032 (0.016 to 0.047)a
On chemotherapy/radiotherapy
Yes 0.755 (0.181) 0.730 (0.272) 0.025 (0.007 to 0.043)a
No 0.854 (0.179) 0.845 (0.219) 0.008 (0.000 to 0.016)a
Mode of administration
Self-administered 0.820 (0.175) 0.807 (0.236) 0.013 (0.004 to 0.022)a
Interviewer-administered 0.722 (0.257) 0.684 (0.342) 0.038 (0.003 to 0.073)
aEquivalence was confirmed
bNon-equivalence was confirmed
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and health status, respectively. The mean deterioration in
patients with worsened performance status was −0.096
and −0.071 based on the valuation- and mapping-derived
indices, respectively (difference = 0.015, 90 % CI = −0.055
to 0.025); the mean deterioration for patients with wors-
ening health status was −0.151 and −0.168 based on the
two indices (difference = 0.017, 90 % CI = −0.076 to 0.110).
Table 4 presents the effect size for detecting a change in
the health indicators, adjusted for the corresponding EQ-
5D-5L utility index score at baseline. Similar to that for
discriminatory ability, although the mapping-derived score
showed a larger effect size than the valuation-derived
score for most indicators, the 90 % CI was within the
equivalence margin for all the health indicators.
In patients who reported no change in performance sta-
tus (N = 138), the ICC was 0.832 and 0.710 for the valu-
ation- and mapping-derived index score, respectively,
resulting in a difference of 0.121 (90 % CI = 0.051 to
0.198). In patients reporting no change in health status
(N = 92), the respective ICCs were 0.793 and 0.607; the
difference was 0.186 (90 % CI = 0.078 to 0.307). There
was no overlap between the CIs and the equivalence
margin of −0.05 to 0.05, indicating non-equivalence.
Bland-Altman plots confirm the better test-retest reli-
ability of the valuation-derived index score than the
mapping-derived score in both groups of patients
(Fig. 2). Take patients who reported no change in per-
formance status for example, the 95 % limits of agree-
ment for the mapping-derived score were wider and 2
patients (1.4 %) in relatively poor health status had dra-
matically different baseline and follow-up scores based
on the mapping approach. One of these two patients
improved from ‘unable to walk about’ at baseline to
‘moderate problems in walking about’ at follow-up, with
the corresponding change in score being 0.717 for the
mapping-derived index and 0.221 for the valuation-
derived index; the other patient deteriorated from
‘slight problems in performing usual activities’ at base-
line to ‘unable to perform usual activities’ at follow-up,
with the corresponding score change being −0.709 and
−0.141 for the mapping- and valuation-derived indices,
respectively.
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Fig. 1 Bland-Altman plots of baseline EQ-5D-5L utility using valuation- and mapping-derived index scores
Table 3 Discriminative ability of the two EQ-5D-5L indices
Health indicator Effect size (standard error) Difference in effect size
(90 % confidence interval)Valuation-derived index score Mapping-derived index score
Oncologist-assessed performance status 0.115 (0.012) 0.153 (0.016) −0.038 (−0.048 to −0.027)a
Patient’s self-assessed performance status 0.141 (0.010) 0.188 (0.014) −0.047 (−0.057 to −0.038)
Current evidence of disease (present vs absent) 0.122 (0.022) 0.156 (0.029) −0.035 (−0.053 to −0.017)
On chemotherapy/radiotherapy (yes vs no) 0.099 (0.022) 0.115 (0.030) −0.016 (−0.035 to 0.002)a
FACT-B total score (per 20-point increment) 0.112 (0.008) 0.135 (0.012) −0.023 (−0.031 to −0.015)a
FACT-G total score (per 20-point increment) 0.134 (0.010) 0.165 (0.015) −0.031 (−0.041 to −0.021)a
EQ-VAS (per 20-point increment) 0.100 (0.010) 0.124 (0.014) −0.023 (−0.032 to −0.014)a
aEquivalence was confirmed
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Discussion
In this study, we found that the EQ-5D-5L indices de-
rived from the mapping and direct valuation approaches
are largely equivalent in patients with breast cancer. The
sensitivity of the two indices to difference and change in
health status defined by other measures are mostly
equivalent, their score values are equivalent or ex-
changeable for the study sample and most of its sub-
groups. Moreover, the two indices exhibited very similar
magnitude of change in utility among patients who ex-
perienced change in performance or health status. These
results provide strong evidence for the validity of van
Hout et al’s mapping function for use in both clinical re-
search and economic evaluations. Since the EQ-5D-5L
values based on direct valuation may not be available in
the near future, our study is an important reference to
users of the EQ-5D-5L mapping function.
The good performance of van Hout et al’s mapping
function is not surprising since the health dimensions
covered by the two EQ-5D questionnaires are identical.
The only difference is the (number of ) levels used in the
two descriptive systems. Moreover, this function does
Table 4 Responsiveness to change of the two EQ-5D-5L index scores
Health indicator Effect size (standard error) Difference in effect size
(90 % confidence interval)Valuation-derived index score Mapping-derived index score
Reported a change in performance status (N = 78)
Change in self-assessed performance status 0.064 (0.016) 0.071 (0.025) −0.007 (−0.025 to 0.011)a
Change in FACT-B total score (per 20-point increment) 0.106 (0.024) 0.109 (0.038) −0.003 (−0.030 to 0.024)a
Change in FACT-G total score (per 20-point increment) 0.119 (0.027) 0.126 (0.042) −0.007 (−0.037 to 0.024)a
Change in EQ-VAS (per 20-point increment) 0.097 (0.022) 0.108 (0.034) −0.011 (−0.035 to 0.014)a
Reported a change in health status (N = 129)
Patient’s self-rated change in health status 0.044 (0.007) 0.055 (0.011) −0.010 (−0.019 to −0.002)a
Change in FACT-B total score (per 20-point increment) 0.081 (0.018) 0.081 (0.029) 0.001 (−0.019 to 0.020)a
Change in FACT-G total score (per 20-point increment) 0.101 (0.020) 0.107 (0.029) −0.007 (−0.029 to 0.015)a
Change in EQ-VAS (per 20-point increment) 0.114 (0.017) 0.142 (0.026) −0.028 (−0.048 to −0.008)a
aEquivalence was confirmed
a
b
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Fig. 2 Bland-Altman plots of the baseline and follow-up EQ-5D-5L index derived from direct valuation and mapping in patients who reported no
change in a self-assessed performance status and b health status
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not take the form of a regression model and therefore
avoids the prediction bias caused by regression to the
mean, an issue observed in mapping functions using a
regression model [9, 36–38] and recently criticized by
Fayers and Hays [11].
It should be noted, however, the over-time reliability
of the mapping-derived EQ-5D-5L index score was
poorer than the valuation-derived index score, although
the reliability of both indices is considered good based
on the psychometric criterion of ICC > 0.70. The lower
reliability means that larger measurement errors are
contained in the index score, which was also suggested
by the greater score dispersion in the baseline survey.
Larger measurement error or data variability would lead
to greater uncertainty in results of statistical analysis, for
example, the larger standard errors of the effect size
measure for the mapping-derived index (see Tables 3
and 4). This issue can be solved by increasing the sample
size. Nevertheless, we found that the reliability of the
mapping-derived index may be poor among individuals
who experience extreme health problems. This should
be due to the fact that the utility values for such health
states are lower according to the EQ-5D-3L value set. As
a result, the change in index scores corresponding to
health-state transitions between extreme problems and
other level of problems based on the EQ-5D-3L value
set is larger than that based on the EQ-5D-5L value set.
The possibly poor reliability may also suggest an issue of
the mapping function itself. It is possible that patients
experiencing extreme problems were insufficiently repre-
sented in the study sample used to develop the mapping
function, and therefore the predictive errors are large for
extremely impaired health states.
Another issue associated with the use of the mapping
function is lower utility values for patients experiencing
extreme health problems, as compared to the value set
estimated from direct valuation. The difference could be
due to the prediction bias of the mapping function. It is
more likely due to the fact that the lowest possible EQ-
5D-3L value (−0.654) is much lower than that of EQ-5D-
5L (−0.224), although the corresponding health states are
identical. The magnitude of the difference suggests that it
is unlikely purely due to random measurement errors in
the EQ-5D-3L and EQ-5D-5L valuation studies. Rather, it
should be due to the time trade-off techniques used in the
two Spanish valuation studies. Health states worse than
dead were measured using the conventional and lead-time
time trade-off techniques [27], respectively, in the Spanish
EQ-5D-3L and EQ-5D-5L valuation studies. Although
there are no head-to-head comparisons of the utility values
measured using the two time trade-off variants, the nu-
ance of the different time trade-off questions and prompts
used in the two valuation studies might have somehow
caused systematic difference in the resultant utility values.
How much this issue impacts on the validity of the map-
ping function in empirical studies would depend on the
proportion of extremely poor health states in the study
sample. In the case of the present study where less than
5 % of the sample experienced extreme health problems,
the overall equivalence between the two value sets was not
affected.
The two issues of the mapping function caution its use
in individuals experiencing extreme health problems or
study samples comprising a larger proportion of such in-
dividuals. In such circumstances, the mapping-derived
EQ-5D-5L index score would be neither reliable nor
equivalent to the index score derived from an EQ-5D-5L
valuation study.
A major limitation of this study is that the EQ-5D-5L
data (Singapore), the mapping function (multiple Euro-
pean countries), and the directly measured utility values
(Spain) were from different populations. Noise could
have been introduced into our analysis because of these
differences. Nevertheless, for countries where EQ-5D
values are not available, it is a common practice to apply
the values from another country. For example, prior to
the development of the Singaporean EQ-5D-3L values,
the Japanese and UK values were applied in Singapore
[22, 23]. Moreover, it is unlikely that Spanish patients
with breast cancer would respond to the EQ-5D-5L
questionnaire in a very different way than their counter-
parts in Singapore. Nevertheless, the findings of our
study may not be generalizable to other patient popula-
tions or existing value sets of other countries. Hence,
studies such as the present one should be conducted
with new patient samples and other valuation-derived
EQ-5D-5L value sets once available to further assess this
mapping function.
In summary, the mapping function developed by van
Hout et al. is likely to generate equivalent EQ-5D-5L
utility values to those derived from direct valuation of
the EQ-5D-5L health states in patients with breast can-
cer. The mapping-derived EQ-5D-5L index score can be
as discriminative and responsive as the index score using
directly measured utility values. The performance of this
mapping function in other patient populations should be
assessed in future studies.
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